Protalix completes enrollment in OPRX-106 phase II clinical trial
Protalix BioTherapeutics announced the completion of enrollment in the company's phase II clinical trial evaluating OPRX-106, the company's oral antiTNF product candidate, in patients with ulcerative colitis, or UC. OPRX-106 is the company's proprietary plant cell-expressed recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain. When administered orally and while passing through the digestive tract, the plant cells function as a natural delivery capsule, having the unique attribute of a cellulose cell wall, which makes them resistant to degradation compared to proteins produced via mammalian cell expression systems. The company expects to report top-line results from this study in the first quarter of 2018.